SCHEMBL25046532

SCHEMBL25046532

O=C(OCCOCCNC(=S)Nc1ccc2c(c1)C(=O)OC21c2ccc(O)cc2Oc2cc(O)ccc21)Oc1ccc2nc(C(=O)ON3C(=O)CCC3O)ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MIF P14174 1/20 0.46
▸ TTR P02766 1/20 0.46
▸ NAALAD2 Q9Y3Q0 6/20 0.45
▸ FOLH1 Q04609 2/20 0.45
▸ NQO1 P15559 1/20 0.42
▸ RORC P51449 1/20 0.42
▸ FTO Q9C0B1 1/20 0.40
▸ NR1H2 P55055 1/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ KEAP1 Q14145 1/20 0.39
▸ DRD2 P14416 3/20 0.39
▸ DRD1 P21728 3/20 0.39
▸ MAP1LC3B Q9GZQ8 1/20 0.39
▸ P2RY14 Q15391 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29861565 0.91 TTR (0.49) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL23458544 0.91 TTR (0.49) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL29861397 0.87 TTR (0.56) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL23458537 0.87 TTR (0.56) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL25046515 0.84 TTR (0.51) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL29861448 0.82 TTR (0.51) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL23458566 0.82 TTR (0.51) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL29861238 0.80 TTR (0.59) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL23458565 0.80 TTR (0.59) MIFTTRNAALAD2FOLH1NQO1
SCHEMBL25045481 0.77 TTR (0.53) MIFTTRNAALAD2FOLH1NQO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046947-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046947-A1 REACTIVE CONJUGATES FCGR3B, FCGR1A, FCGR2A MIF 2775/4885TTR 1071/4885NAALAD2 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback